ABSTRACT: rhBMP-2 is an osteoinductive protein that, when administered locally, results in the induction of new bone tissue at the site of implantation. The osteoinductive properties of rhBMP-2 first were demonstrated by implantation at ectopic (nonbony) sites in rodents. BMPs are the only protein factors known to induce new, ectopic bone. rhBMP-2/Absorbable Collagen Sponge (ACS) is a TEMP that combines rhBMP-2 with a matrix for implantation. rhBMP-2/ACS is used in long bone fracture repair and spinal fusion. The development of rhBMP-2 protein as the active ingredient in the rhBMP-2/ACS product is summarized. Four aspects of rhBMP-2 development are covered: protein structural characterization, functional characterization, purity analysis and design of comparability studies to support changes in the manufacturing process. Topics discussed include rhBMP-2 as a "biologic" and as a constituent of a combination TEMP. The lessons learned during the development of rhBMP-2/ACS may allow general insight into the development of future standards for TEMPs that contain biologically active proteins.
Introduction
Bone morphogenetic proteins were initially isolated from bovine bone based upon their ability to induce cartilage and bone in a rat ectopic assay system [1] . BMPs are the only protein factors known to induce new, ectopic bone. The activity of bone extracts was used to identify and clone a family of genes known as the BMPs (or GDFs, growth and differentiation factors), members of the multigene TGF-β superfamily of growth and differentiation factors [2] . Proteins in this superfamily share seven conserved cysteines and have varying degrees of sequence homology with each other. The cDNA for human BMP-2 was cloned and expressed in Chinese hamster ovary (CHO) cells. CHO cells efficiently glycosylate the protein and process the large precursor molecule by removal of the signal peptide from prepro rhBMP-2 followed by removal of the propeptide region ( Figure 1 ) [3] .
The processed, active protein is a disulfide-linked dimer that resembles natural BMP-2 derived from bovine bone. The purified protein has two NH 2 -termini resulting from differential cellular processing, starting at either Thr 266 or Gln 283 . Gln 283 spontaneously cyclizes to pyroglutamate in aqueous medium [4] . These three NH 2 -terminal isoforms, designated T266, Q283 and <Q283, form six covalent dimers (Figure 1 ).
FIG. 1-Cellular processing of Prepro rhBMP-2.
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FIG. 2-rhBMP-2/ACS product preparation.
rhBMP-2/ACS achieves osteoinduction by a pharmacologic mechanism of action attributable to rhBMP-2. rhBMP-2 binds to receptors on the surface of mesenchymal cells and causes these cells to differentiate into cartilage-and bone-forming cells. These differentiated cells form trabecular bone as the ACS is degraded, with vascular invasion evident at the same time [11] . The bone formation process develops from the outside of the implant towards the center until the entire rhBMP-2/ACS implant is replaced by bone.
The following discussion focuses on the development of the rhBMP-2 component of the rhBMP-2/ACS product. Characterization and assay development for rhBMP-2 were, for the most part, typical of those activities associated with a parenteral protein biologic. However, the final product contains both rhBMP-2 and ACS. Additional characterization of rhBMP-2 in combination with ACS was needed to assure proper functioning of the entire implantable product.
Materials and Methods
rhBMP-2
rhBMP-2 test samples were derived from protein batches produced at Wyeth BioPharma (Andover MA or Cambridge MA). The protein concentration of these samples was typically 3-8 mg/mL in various formulation buffers.
High Performance Liquid Chromatography (HPLC)
All protein and peptide HPLC separations were carried out on HPLC systems from Waters Corporation using Vydac, Pharmacia, Phenomenex or Tosoh HPLC columns.
For the peptide map, rhBMP-2 was reduced with dithiothreitol and alkylated with iodoacetic acid. The reduced and alkylated protein was desalted and buffer exchanged into endoproteinase Asp-N digestion buffer by gel filtration and digested at 37˚C for 90 min. The reaction was quenched with trifluoroacetic acid and peptides were injected onto a Tosoh Super ODS C18 column. Solvent A was 6 mM trifluoroacetic acid (TFA) and 4 mM heptafluorobutyric acid (HFBA) in water, solvent B was 95% acetonitrile, 5% water, 6 mM TFA, 4 mM HFBA. Peptide separation occurred between 11% and 55% solvent B.
Carbohydrate Removal
High mannose-type N-linked glycans were removed from the protein by endoglycosidase H (Endo H) treatment. rhBMP-2 (100 µg) was treated with Endo H (10 milliunits, Oxford Glycosystems) overnight at 37 ºC at pH 6.5 in a histidine, arginine buffer. Extent of glycan removal was judged by SDS-PAGE.
Mass Spectrometry (MS)
Intact protein mass was determined by online liquid chromatography/MS (LC-MS) with separation on a microbore phenyl reversed phase (RP)-HPLC column followed by MS with electrospray ionization on a hybrid quadrupole time-of-flight mass spectrometer (Micromass Q-TOF). Peptide masses were obtained by LC-MS with separation on a C18 RP-HPLC column followed by electrospray ionization MS on a ThermoFinnigan LCQ instrument.
Bioassays
The in vitro W-20 bioassay was performed as described in ASTM standard F2131-02. The in-vivo Use Test was performed as described in [12] .
Results and Discussion
Protein Primary Structure and Posttranslational Modifications
The structure of the purified protein was characterized by Edman degradation, mass spectrometry and various chromatographic techniques. The complete protein sequence of mature rhBMP-2 in drug substance was determined by LC-MS of the peptide map to be identical to that predicted from the nucleotide sequence of the cDNA ( Figures 3 and 4 , Table 1 ).
rhBMP-2 contains a single N-glycosylation site per subunit at Asn 338 , which is occupied. The N-linked oligosaccharides present at this site were characterized by 1H nuclear magnetic resonance and carbohydrate fingerprinting and determined to be high mannose structures, containing between 5 and 9 mannose residues. No O-linked oligosaccharides were found. The mixture of intact protein isoforms overlaid with carbohydrate heterogeneity was well resolved by electrospray ionization hybrid quadrupole time-of-flight (ESI Q-TOF) MS (the mass accuracy of the instrument is better than 0.005%). All expected glycoforms of each NH 2 -terminal isoform were found in drug substance. The mass data for all species were consistent with results obtained from the LC-MS analysis of the peptide map for the glycopeptides and NH 2 -terminal isoform-related peptides ( Figure 5 and Table 2 ). All observed masses for the dimer agreed with the expected masses with 0.004% mass accuracy and no unexpected masses were observed. 2 Modification is consistent with methionine sulfoxide at position 388 based upon fragmentation pattern in the mass spectrometer. 3 Modification is consistent with isoAsp 270 based on mass analysis, NH 2 -terminal sequencing and Asp-N selectivity. 4 Hydroxyproline 318 based on mass analysis, NH 2 -terminal sequencing and amino acid analysis. 5 Modification is consistent with methionine sulfoxide at position 371 based upon fragmentation pattern in the mass spectrometer. 6 Modification is consistent with isoAsp 335 based on mass analysis and Asp-N selectivity. 
FIG. 5-Intact
Impact of the Collagen Matrix on rhBMP-2 Structure
rhBMP-2 solution is applied to the collagen sponge prior to surgical implantation. To allow flexibility in surgical schedules, it was necessary to have a window of time after product preparation and before implantation. The structural integrity and in vitro bioactivity of the rhBMP-2 component of the product is well characterized and is controlled by release testing. However, this testing does not assess the effect of contact with the ACS on the rhBMP-2 structure and activity.
An experiment was performed to determine whether the ACS had an impact on the structural integrity of the incorporated rhBMP-2 over the desired pre-surgery time window of the product after wetting. rhBMP-2 was separately combined with three different lots of ACS and incubated for 3.5 h at room temperature. This time period is 1 h 15 m beyond the maximum time limit for the pre-implantation period after the rhBMP-2 and the ACS are combined in the operating room. The rhBMP-2/ACS samples were extracted with citrate buffer. The collagen remained insoluble under these conditions, allowing peptide map characterization of rhBMP-2 ( Figure 6 ). Recovery of rhBMP-2 was 81% ±1% of the loaded protein, and no significant changes in the peptide map profile were found, suggesting that rhBMP-2 structure is not altered by extended contact with the ACS.
Biological Activity
Description of Bioassays-Two bioassays were employed in development of rhBMP-2, the in vitro W-20 assay and the in vivo Use Test (rat ectopic assay).
The W-20 assay is based upon rhBMP-2 dose-dependent receptor-mediated gene induction of alkaline phosphatase in the mouse W-20 stromal cell line [13, F2131-02] . This assay is a release test for rhBMP-2 drug substance and vialed protein and it is also used as the assay that defines the World Health Organization's International Unit of rhBMP-2 activity. The biological activity of each sample is determined relative to a reference standard with an assigned potency.
The rat ectopic implant model is a classic assay system for bone morphogenetic protein activity [14] . This assay has been modified and standardized for testing of rhBMP-2/ACS, and the assay is called the Use Test. It has been utilized during development of the product as a release assay for rhBMP-2/ACS product, and for assessing stability. It demonstrates that rhBMP-2/ACS has its intended activity, i.e., the local induction of bone. For each test, the rhBMP-2 component is diluted to 0.1 mg/mL and combined with an appropriately sized ACS section. Ten samples are implanted subcutaneously into five rats (bilateral implants). In addition, two negative control implants, buffer/ACS, are implanted into a rat. After 14 days, the implants are removed and processed for histology and scored for bone content. The amount of induced bone present in a section is assessed using a scoring scale of 0 (no bone present) to 5 (all of the implant is bone). The amount of bone formation is determined as the total area of bone including bone marrow that has been induced. Biological Activity of Protein Isoforms-It was important to determine whether the major product isoforms were active for process consistency reasons. If one or more of the isoforms were found to be inactive, the purification process would have been modified to reduce or eliminate those species. The six NH 2 -terminal isoforms were isolated and tested for biological activity in-vitro and in-vivo. Isoforms were purified by cation exchange chromatography. Tables 3 and 4 show the activity results. T266-containing isoforms had lower activity than the Q283 forms in vitro, but had similar activity to that of the Q283 forms in-vivo. 1 Rat ectopic bone scoring system described in text; ACS was used as the matrix.
2 Unfractionated rhBMP-2.
Given these activity results, all NH 2 -terminal isoforms were considered appropriate for inclusion in the rhBMP-2/ACS implantable product.
Although the N-linked glycosylation site is fully occupied as judged by the retention time and mass of the glycosylated peptide in the peptide map, it was important to determine the role of the carbohydrate in biological activity. A production process failure might result in unglycosylated protein in the drug substance. Since un-or underglycosylated species were not found in rhBMP-2 batches, rhBMP-2 was enzymatically demannosylated by Endo H treatment. This treatment resulted in protein with the high mannose glycan trimmed back to one Nacetylglucosamine. Removal of the mannose did not have a significant effect on either in vitro or in vivo activity (Tables 5 and 6 ). Endo H-Treated 4.0 ± 0.0 1 rhBMP-2 was treated with Endo H as described in Materials and Methods. Deglycosylated rhBMP-2 was purified from Endo H by cation exchange HPLC and C4 RP-HPLC. Control rhBMP-2 was taken through the same procedure without the addition of enzyme. 2 The error shown is the standard error of the mean of duplicate determinations. [12] for a description of the rat ectopic bone-forming assay (Use Test). 2 Samples prepared as described in Table 5 . 3 Rat ectopic bone scoring system described in the text; ACS was used as the matrix.
These data indicate that the glycan does not play a significant role in rhBMP-2 biological activity.
Correlation of In-Vitro and In-Vivo Bioassays-
The W-20 cell-based in vitro bioassay was determined to be a relevant indicator of biological activity based upon the correlation of rhBMP-2 activity in this assay with ectopic bone forming activity of rhBMP-2 in the in vivo Use Test.
The shape of the dose response curve in the Use Test, like many in-vivo bioassays, is nonlinear and extremely steep. Nevertheless, because the Use Test assesses bone formation, which is the desired clinical outcome of implantation of rhBMP-2/ACS, the test is considered to be a useful characterization assay. Although the W-20 bioassay does not measure bone formation, it does measure specific induction of alkaline phosphatase (ALP) by rhBMP-2, one of the events on the differentiation pathway to osteoblasts. Detection of bone-specific ALP related to bone formation has clinical relevance. The measurement of ALP from a patient's serum has been used clinically as a surrogate marker to monitor therapies that stimulate bone formation [15] . The imprecision of the Use Test rules out an exact correlation of the Use Test and the W-20 bioassay, however, a general correlation was established that shows that the W-20 bioassay is a relevant surrogate for the Use Test.
The assays were compared by assessing the relative response of the each to rhBMP-2 with intentionally reduced activity. Chemical oxidation of rhBMP-2 with peracetic acid results in specific oxidation of the two methionine residues in each subunit of the rhBMP-2 dimer and decreased in vitro bioactivity. The protein was still dimeric as shown by SDS-PAGE analysis, and no significant differences other than oxidation at methionine was detected in the protein's covalent structure by peptide mapping and mass spectrometry. Characterization of the oxidized protein with near ultraviolet circular dichroism (near UV CD) and tryptophan fluorescence indicated that the tryptophan environment is disrupted [16] . Both methionine residues are near each other in space and are also close to the only two tryptophan residues in the protein. All of these amino acid residues reside in the hydrophobic finger-helix receptor-binding pocket on rhBMP-2. This pocket interacts with the phenylalanine "knob" on the BMP Type I receptor (specifically BMPRIA) [17] . BMPRIA has been shown by Northern blot analysis to be expressed at a high level in the W-20 cell line as well as many other tissues, and therefore the BMP-2/BMPRIA structural information supports the relevance of the use of rhBMP-2 oxidized at the methionine residues as a tool to compare the in-vitro and in-vivo assays. Protein with different degrees of oxidation at the methionine residues was prepared and tested in both the W-20 bioassay and the Use Test. rhBMP-2 fully oxidized at both methionine residues was virtually inactive in both the W-20 bioassay and the Use Test (Table 7) . 1.00 ---0.0 1 rhBMP-2 active substance was oxidized with peracetic acid, then desalted by RP-HPLC. Protein was dried by vacuum centrifugation and reconstituted in formulation buffer. The control was incubated without peracetic acid, and was desalted and reconstituted in formulation buffer. 2 Standard deviation reflects bioassay variability, does not include protein concentration assay variability. 3 The % oxidation was determined from the peptide map, and is expressed as overall oxidation of the D335-L374 and D387-R396 peptides. 4 Bone Score, on a scale of 0-5.
The activity in the W-20 bioassay decreased as the level of oxidation increased. This was PORTER ET AL. ON rhBMP-2 17 also the case in the Use Test; the protein with intermediate levels of oxidation (62% and 87%) had lower activities than the control, but this difference is most striking at the lowest dose, 0.01 mg/mL. Taken together, the structural information and activity data suggest that a single receptor binding domain on rhBMP-2 is responsible for both in-vitro and in-vivo activity and that the W-20 bioassay is a relevant predictor of bone-forming activity of rhBMP-2. The W-20 assay is used as an rhBMP-2 release assay. The Use Test remains in place as a characterization test, but is not used for product release.
Impact of the Collagen Matrix on rhBMP-2 Biological
Activity-In addition to the determination of effect of the ACS matrix on rhBMP-2 structure (see above), the impact of contact with the ACS on the intrinsic bioactivity of rhBMP-2 was also investigated. rhBMP-2 is the active ingredient in the rhBMP-2/ACS. Although the rhBMP-2/ACS combination is active and induces bone growth, it was not known if the ACS partially inactivates the rhBMP-2.
rhBMP-2 was soak-loaded onto ACS, incubated and extracted as described above (Impact of the Collagen Matrix on rhBMP-2 Structure). The extracted rhBMP-2 was tested for bioactivity in the W-20 assay. There was no significant effect of the ACS on activity (Table 8) . 
Purity Analysis
Impurities encountered during purification of recombinant protein pharmaceuticals may include adventitious viruses and bacteria, host cell-derived proteins and DNA, process-derived contaminants such as cell culture additives (e.g., methotrexate and insulin) and product-related impurities, such as incompletely processed product species. The rhBMP-2 process was designed to remove all of these potential impurities. In most cases, the ability of the purification process to remove these impurities routinely allowed for "validation of removal" studies to substitute for batch-to-batch release assays on the protein. However, general tests for protein purity were implemented in development and remain in place as commercial release assays to ensure that potential process failures that might result in unacceptable levels of impurities in the protein batches are detected. These tests include RP-HPLC, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and size exclusion HPLC (SE-HPLC).
The RP-HPLC assay can resolve propeptide, the 80 kDa and 110 kDa pro species and dissociable dimer from the main covalent dimer product species (see Figure 1 ). This assay can also detect host cell protein. SDS-PAGE is a general test for protein impurities. Two types of SDS-PAGE are performed as release assays: SDS-PAGE with Coomassie Blue stain and SDS-PAGE with silver stain. The latter test is run with a bovine serum albumin control loaded at 1% of the weight of the product to serve as a semi-quantitative measure of potential protein impurities. SE-HPLC can detect and quantitate high molecular weight rhBMP-2 species that can result from self-association of the protein.
Comparability Studies
The overall goal of comparability studies is to demonstrate biochemically and non-clinically the similarity between product produced with a current production process and that produced with a newly developed production process. If successful, a comparability program may allow clinical or commercial use of product produced with the new process without clinical trials.
The rhBMP-2 production process underwent improvements during clinical development. The goal of the initial comparability program for rhBMP-2 drug substance was to demonstrate comparability between material employed in early clinical trials (produced with an earlier process) and material that would supply commercial launch (produced with an improved process). Subsequent comparability programs will focus on a comparison of initial commercial drug substance and that produced with a larger scale, more economic process.
The comparability program to support active substance process improvements was comprehensive in scope and included extensive studies of the manufacturing process and the rhBMP-2 protein. The process assessment included comparison of impurity removal capacity of the processes and comparison of results of in-process testing, such as degree of cell lysis and product yield at each step. Protein testing included a comparison of release assay results from testing of the rhBMP-2 produced with the clinical and commercial processes. Due to material limitations, three batches from each process were compared side-by-side. Future comparability programs will compare the dataset generated during testing of multiple commercial batches with data from testing of multiple batches produced with a scaled up process.
Additional characterization was also performed in a side-by-side manner on three batches produced by each process. This characterization included more involved studies that are not routinely performed for product release, such as LC-MS of the peptide map, intact molecular mass analysis and near UV CD, forced degradation and non-clinical testing.
All results indicated that the drug substance produced with the commercial process was comparable to that produced with the clinical process. All masses detected during mass analyses of the peptides or the intact protein were expected. The higher order structure of the proteins was also comparable as determined by near UV CD. A side-by-side forced degradation study was carried out. rhBMP-2 is a stable protein in its recommended storage conditions (-80 ºC for bulk protein and room temperature for protein in single use vials). To compare the degradation pathways of rhBMP-2 produced by both processes, drug substance samples were stressed at 37-40 ºC for one week. These conditions resulted in expected chemical changes to the protein. The primary degradation pathways observed for rhBMP-2 in liquid at 37-40 °C were isoAsp formation at two Asp residues and increased cyclization of the NH 2 -terminal Gln. A low level of HMW species also formed. Despite these structural changes, no loss of bioactivity was detected, and the results indicated that the protein produced by the commercial and clinical processes were comparable.
Non-clinical functional comparability studies included a comparison of the clinical and commercial rhBMP-2 in the Use Test and in an implant pharmacokinetic model in rats. As in the other characterization studies, three batches from each process were compared in a side-by-side manner in both studies. The bone-forming results and pharmacokinetic parameters were not sigificantly different and the two drug substances were judged to be comparable.
Regulatory Pathway
After negotiations with FDA and the EMEA following the marketing applications, rhBMP-2/ACS was approved in the European Union (EU) and in the United States for orthopedic trauma and spinal fusion, respectively. Table 9 shows the different regulatory pathways for the product. 
Lessons Learned
There were multiple lessons learned during the development and approval process for rhBMP-2/ACS. For drug substance development, these include:
• Although an improved manufacturing process may consistently eliminate or significantly reduce undesirable species in the protein that were present in clinical trial material, the release assays should be configured to detect these species. This provides added assurance that an aberrant manufacturing run would be identified during testing of the product.
• An adequate supply of protein produced by earlier processes should be reserved for comparability studies. This would allow side-by-side comparison of old and new drug substance with contemporary release assays and characterization methods. Particularly important are protein batches that were employed in preclinical toxicology and early clinical trials.
• Protein degradation products, such as oxidized and deamidated protein, should be generated and tested in all assays during early assay development. This would avoid reconfiguraton of the assay to resolve these species later in development.
• Determination of the solubility profile of the protein with respect to ionic strength and pH will allow a better understanding of the protein/formulation and protein/matrix relationship.
• Major protein isoforms should be isolated and characterized both in vitro and in vivo early in purification process development. Information from these activities will allow adjustment of the purification process to yield appropriate product species.
• Correlation of the output of an in-vitro bioassay to that of a relevant in vivo assay may allow the exclusive use of the in vitro bioassay for lot release. This will simplify product release testing.
